Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Leukemia, Myeloid, Acute 12Multiple Myeloma 9Lymphoma 8Breast Neoplasms 8Lymphoma, Non-Hodgkin 7Hodgkin Disease 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Neuroblastoma 6Lymphoma, Large B-Cell, Diffuse 4Central Nervous System Neoplasms 4Burkitt Lymphoma 4Sarcoma 3Medulloblastoma 3Leukemia 3Brain Neoplasms 3Anemia, Refractory, with Excess of Blasts 3Wilms Tumor 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Retinoblastoma 2Recurrence 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms, Plasma Cell 2Malignant mesenchymal tumor 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Follicular 2Leukemia, Myelomonocytic, Acute 2Leukemia, Monocytic, Acute 2Leukemia, Megakaryoblastic, Acute 2Leukemia, Erythroblastic, Acute 2

Interventions

pegfilgrastim 1Taxes 1Platinum 1Paclitaxel 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Doxorubicin 1Cisplatin 1Carboplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Recurrent Uterine Corpus Carcinoma × Granulocyte Colony-Stimulating Factor × Clear all
NCT00063999 2021-10-19

Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

GOG Foundation

Phase 3 Completed
1,381 enrolled 12 charts
Gynecologic

Recurrent Uterine Corpus Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡